NASDAQ:LLIT - Lianluo Smart Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.42 -0.10 (-6.59 %) (As of 05/24/2019 09:00 AM ET)Previous Close$1.52Today's Range$1.4171 - $1.5352-Week Range$0.84 - $2.40Volume1,377 shsAverage Volume7,742 shsMarket Capitalization$24.92 millionP/E RatioN/ADividend YieldN/ABeta1.5 ProfileChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lianluo Smart Limited, through its subsidiaries, designs, develops, markets, and distributes medical products and medical components primarily in the People's Republic of China. The company offers medical devices, including sleep apnea diagnostic products, general hospital products, medical compressors, and related supporting products, such as laryngoscope. It also distributes medical products designed and manufactured by other companies. The company sells its products primarily through distributors; and directly to hospital, physical examination centers, and governmental agencies, as well as to individuals. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was founded in 2003 and is headquartered in Beijing, the People's Republic of China. Lianluo Smart Limited operates as a subsidiary of Hangzhou Liaison Interactive Information Technology Co., Ltd. Receive LLIT News and Ratings via Email Sign-up to receive the latest news and ratings for LLIT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LLIT Previous Symbol CUSIPN/A CIK1474627 Webhttp://www.lianluosmart.com/ Phone86-010-8860-9850Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio0.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$560,000.00 Price / Sales44.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book7.87Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees129 Outstanding Shares17,588,000Market Cap$24.92 million Next Earnings DateN/A OptionableNot Optionable Lianluo Smart (NASDAQ:LLIT) Frequently Asked Questions What is Lianluo Smart's stock symbol? Lianluo Smart trades on the NASDAQ under the ticker symbol "LLIT." Has Lianluo Smart been receiving favorable news coverage? News headlines about LLIT stock have been trending somewhat positive on Friday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lianluo Smart earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Lianluo Smart's key competitors? Some companies that are related to Lianluo Smart include RenovaCare (RCAR), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), Nuvectra (NVTR), Motus GI (MOTS), CAS Medical Systems (CASM), STRATA Skin Sciences (SSKN), Repro-Med Systems (REPR), RA Medical Systems (RMED), Titan Medical (TMDI), Invo Bioscience (IVOB), Pro-Dex (PDEX), Spectral Medical (EDTXF), AIT Therapeutics (AITB) and Arch Therapeutics (ARTH). What other stocks do shareholders of Lianluo Smart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lianluo Smart investors own include Catalyst Biosciences (CBIO), Avid Bioservices (CDMO), Inovio Pharmaceuticals (INO), Sonoma Pharmaceuticals (SNOA), Rexahn Pharmaceuticals (RNN), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Celsion (CLSN), Cardiome Pharma (CRME) and CTI BioPharma (CTIC). Who are Lianluo Smart's key executives? Lianluo Smart's management team includes the folowing people: Mr. Ping Chen, CEO, GM & Director (Age 56)Ms. Yingmei Yang, Interim Chief Financial Officer (Age 48)Mr. Fei Dong, Director of OperationsDr. Xiaoqing Wang Ph.D., Chief Technology OfficerLisa Zhou, Investor Relations Mang. How do I buy shares of Lianluo Smart? Shares of LLIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Lianluo Smart's stock price today? One share of LLIT stock can currently be purchased for approximately $1.4171. How big of a company is Lianluo Smart? Lianluo Smart has a market capitalization of $24.92 million and generates $560,000.00 in revenue each year. Lianluo Smart employs 129 workers across the globe. What is Lianluo Smart's official website? The official website for Lianluo Smart is http://www.lianluosmart.com/. How can I contact Lianluo Smart? Lianluo Smart's mailing address is Room 2108 21st Floor China Railway Construction Building No. 20 Shijingshan Road, Beijing F4, 100040. The medical equipment provider can be reached via phone at 86-010-8860-9850 or via email at [email protected] MarketBeat Community Rating for Lianluo Smart (NASDAQ LLIT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 68 (Vote Outperform)Underperform Votes: 58 (Vote Underperform)Total Votes: 126MarketBeat's community ratings are surveys of what our community members think about Lianluo Smart and other stocks. Vote "Outperform" if you believe LLIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLIT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.